J&J seeks to release COVID-19 vaccine by 2021

By The Science Advisory Board staff writers

March 30, 2020 -- Johnson & Johnson has selected a lead COVID-19 vaccine candidate from a number of options it has been working on since January. The company hopes to release a vaccine by 2021.

The lead vaccine has been developed in partnership with Janssen Pharmaceuticals and Beth Israel Deaconess Medical Center using Janssen's AdVac technology, the company said.

Johnson & Johnson plans to begin human clinical studies on the vaccine candidate by September 2020, and anticipates the first batches of it could be available for emergency use authorization from the U.S. Food and Drug Administration (FDA) in early 2021.

The company also plans to scale its manufacturing capability so it can produce more than 1 billion doses of the vaccine, it said.

The company's vaccine development efforts have been supported by the Biomedical Advanced Research and Development Authority (BARDA), a partnership that is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services.

Dynavax, Clover partner for protein-based COVID-19 vaccine
A new research collaboration between Dynavax Technologies and Clover Biopharmaceuticals aims to develop a vaccine candidate to prevent COVID-19. The partnership,...
DOD grant accelerates SARS-CoV-2 vaccine manufacturing
The U.S. Department of Defense (DOD) has awarded Ology Bioservices and Inovio Pharmaceuticals an $11.9 million contract to rapidly manufacture DNA...
Sengenics offers COVID-19 antigens for vaccine development
Sengenics announced that it has COVID-19 antigens available for both research and commercial vaccine development purposes for sale.
Breakthrough in coronavirus research provides map for vaccines
Critical research reveals the 3D atomic-scale map of the spike protein of the 2019 novel coronavirus (2019-nCoV), which is responsible for infecting humans....
Personalized cancer vaccines now possible due to discovery of cancer frameshift neoantigens
Researchers from Arizona State University's Biodesign Institute demonstrated experimental proof-of-concept that cancer mutations produce individual neoantigens,...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter